All In Biotech

Drug Trial Radar · NCT00988039

Europe-Africa Research Network for Evaluation of Second-line Therapy

A Randomised Controlled Trial to Evaluate Options for Second-line Therapy in Patients Failing a First-line 2NRTI + NNRTI Regimen in Africa

Last checked: Nov 19, 2026Latest source record: Apr 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,277

Actual

Start

Mar 2010

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
Justine BolesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Oct 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined failure on a first-line nucleoside reverse transcriptase inhibitor (NRTI) and NNRTI-containing regimen with probable extensive NRTI and NNRTI resistance mutations.

Conditions

  • Human Immunodeficiency Virus
  • HIV

Interventions

  • Aluvia + 2NRTIsDrug

    Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.

  • Aluvia + raltegravirDrug

    Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily raltegravir (400mg) twice daily

  • Aluvia monotherapyDrug

    Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily raltegravir (400mg) twice daily for the first 12 weeks only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Good HIV disease control defined as a composite endpoint consisting of all of: - No new WHO stage 4 events - CD4 count >250 cells/mm3 - viral load <10,000 copies/ml or >10,000 copies/ml with no PI resistance mutationsTime frame: week 96

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • AMPATH Centre at Moi Teaching Referral Hospital

    Eldoret, Kenya

  • University of Malawi

    Blantyre, Malawi

  • Mzuzu Central Hospital

    Mzuzu, Malawi

  • Joint Clinical Research Centre

    Fort Portal, Uganda

  • JCRC

    Gulu, Uganda

  • JCRC

    Kabale, Uganda

  • JCRC

    Kakira, Uganda

  • Infectious Diseases Institute

    Kampala, Uganda

  • Joint Clinical Research Centre

    Kampala, Uganda

  • San Raphael of St Francis Hospital Nsambya

    Kampala, Uganda

  • Joint Clinical Research Centre

    Mbale, Uganda

  • Joint Clinical Research Centre

    Mbarara, Uganda

  • University Teaching Hospital

    Lusaka, Zambia

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.